non-diabetic proteinuria
Conditions
Interventions
Lisinopril 40 mg, with the addition of valsartan 320 mg (160 mg 1dd2) or placebo, both during low dietary sodium intake and high dietary sodium intake in randomised order.
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age older than 18 year; 2. Chronic non-diabetic renal disease, as established by history, urine analysis, serum biochemistry tests and/or renal biopsy; 3. Creatinine clearance > 30 ml/min/1.73 m; 4. Residual proteinuria > 1 g/24h.
Exclusion criteria
Exclusion criteria: 1. Failure to comply with the above inclusion criteria; 2. Diabetes mellitus; 3. Any contra-indication against the use of ACE inhibitors or AT1 receptor blockers; 4. A history of myocardial infarction, unstable angina, coronary by-pass or CVA during the past 6 months; 5. Heart failure NYHA class III-IV; 6. High rate of renal function loss (decline in creatinine clearance > 6 ml/min/1.73m2 during the previous year); 7. Need for treatment with corticosteroids, NSAID’s or immunosuppressive drugs; 8. Proteinuria > 10 g/24h and hypoalbuminaemia 100 mmHg); 10. Serum potassium > 6 mmol/L.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint will be reduction of proteinuria and blood pressure expressed as percentage change from baseline and analysed with each patient as his or her own control. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Serum creatinine; 2. Circulating RAS parameters; 3. Lipid profile; 4. Adiponectin. | — |
Contacts
Public ContactF. Waanders
University Medical Center Groningen (UMCG), Department of Nephrology, Hanzeplein 1
Outcome results
None listed